Frontlight ResearchEarly access
Melanoma trials in Spain
39 of 50 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleAdjuvant Tebentafusp in High Risk Ocular Melanoma
- Where
- L'Hospitalet de Llobregat, Madrid, Valladolid
- Age
- 18 years and over
- People
- 290 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT06246149 · EU 2023-510333-28-00 - Phase 3Taking peopleRandomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
- Where
- Barcelona, Bilbao, Huelva, Lleida, Madrid, Málaga, Sabadell, Sevilla, Torrejón de Ardoz
- Age
- 18 years and over
- People
- 119 worldwide
- Run by
- Mabxience Research S.L.
See details and how to join2025-521562-95-00 - Phase 3Taking peopleNeoadjuvant Darovasertib in Primary Uveal Melanoma
- Where
- L'hospitalet De Llobregat, Pamplona, Santiago de Compostela, Sevilla, Valladolid
- Age
- 18 years and over
- People
- 520 worldwide
- Run by
- IDEAYA Biosciences
See details and how to joinNCT07015190 · EU 2025-522387-32-00 - Phase 1/2Not yet taking people in SpainA First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
- Where
- Barcelona, Madrid, Sevilla, Valencia
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06413680 · EU 2025-523399-22-00 - Phase 1Active, not recruitingA Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma
- Where
- Badalona, Barcelona, Cáceres, Madrid, Málaga, Sabadell, Santander, Torrejón de Ardoz
- Age
- 18 years and over
- People
- 83 worldwide
- Run by
- Celltrion Inc.
See details and how to join2023-510017-26-00 - Phase 2/3Not yet taking people in SpainA Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Where
- L'Hospitalet de Llobregat
- Age
- 18 years and over
- People
- 280 worldwide
- Run by
- Replimune, Inc.
See details and how to joinNCT06581406 · EU 2023-508784-68-00 - Phase 3Taking peopleTebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- Where
- Barcelona, Madrid, Málaga, Valencia
- Age
- 18 years and over
- People
- 540 worldwide
- Run by
- Immunocore Ltd
See details and how to joinNCT05549297 · EU 2022-502732-39-00 - Phase 3Taking peopleIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Where
- A Coruña, Barcelona, Córdoba, El Palmar, Granada, Las Palmas de Gran Canaria, Madrid, Málaga, Pamplona, Reus, San Sebastián, Santander, Seville, Valencia, Zaragoza
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Immunocore Ltd
See details and how to joinNCT06112314 - Phase 1Taking peopleA Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma
- Where
- Badajoz, Barcelona, Cáceres, Madrid, Málaga
- Age
- 18 years and over
- People
- 34 worldwide
- Run by
- Intas Pharmaceuticals Limited
See details and how to join2025-522307-14-00 - Phase 3Taking peopleEfficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- Where
- Badalona, Barcelona, Donostia, Las Palmas De Gran Canaria, Madrid, Málaga, Murcia, Sevilla, Valencia
- Age
- 18 years and over
- People
- 186 worldwide
- Run by
- Philogen S.p.A.
See details and how to joinNCT03567889 · EU 2023-507119-36-00 - Phase 2Taking peopleEncorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
- Where
- A Coruña, Almería, Barcelona, Burgos, Cáceres, Donostia, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Murcia, Santander, Sevilla, Toledo, Valencia, Valladolid
- Age
- 18 years and over
- People
- 33
- Run by
- Grupo Español Multidisciplinar de Melanoma
See details and how to joinNCT06887088 · EU 2024-513375-40-00 - No phaseTaking peopleResistance Exercise in Patients With Ocular Melanoma
- Where
- Valencia
- Age
- 18 years and over
- People
- 40
- Run by
- University of Valencia
See details and how to joinNCT06970236 - Phase 2Taking peopleEvaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)
- Where
- Barcelona
- Age
- 18 years and over
- People
- 40
- Run by
- Vall d'Hebron Institute of Oncology
See details and how to joinNCT06630611 - Phase 2Taking peoplePhase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
- Where
- Barcelona, Madrid, Valencia
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- IO Biotech
See details and how to joinNCT05280314